Holen Sie sich die Stockscreener-App
85.53
0.08%
-0.07
Handel nachbörslich:
86.00
0.47
+0.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$85.60
Offen:
$85.77
24-Stunden-Volumen:
2.44M
Relative Volume:
1.12
Marktkapitalisierung:
$12.05B
Einnahmen:
$622.01M
Nettoeinkommen (Verlust:
$-271.86M
KGV:
-39.81
EPS:
-2.1484
Netto-Cashflow:
$-45.87M
1W Leistung:
+19.37%
1M Leistung:
+8.42%
6M Leistung:
+27.83%
1J Leistung:
+443.39%
1-Tages-Spanne:
$85.21
$87.93
1-Wochen-Bereich:
$72.62
$95.49
52-Wochen-Spanne:
$15.01
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
85.53 | 12.06B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
BlackRock discloses 10.1% Arrowhead Pharmaceuticals (ARWR) stake in latest 13G/A - Stock Titan
Arrowhead Pharmaceuticals Advances Zodasiran Study for HoFH Trea - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial - GuruFocus
H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data - Investing.com Canada
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Arrowhead Pharmaceuticals, Inc.
Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – BX:HDP1 - TradingView
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1 - TradingView
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo! Finance Canada
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Trefis
ARWR Reiterated by Piper Sandler -- Price Target Raised to $126 - GuruFocus
H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data By Investing.com - Investing.com Canada
Arrowhead shares surge as Phase III plozasiran studies deliver positive pancreatitis data - The Pharma Letter
Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Reports Positive Phase 3 Trial Results - GuruFocus
Arrowhead (ARWR) Sees Significant Stock Surge - GuruFocus
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - TradingView
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $101.6, Implies 36% Upside - TradingView
ARWR Stock Climbs As EU Greenlights REDEMPLO And Analysts Boost Targets - timothysykes.com
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
ARWR Maintained by Chardan Capital -- Price Target Raised to $115 - GuruFocus
Arrowhead Pharmaceuticals Shares Rise After Phase 3 Trials of Plozasiran Meets Primary, Secondary Endpoints - Moomoo
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send? - TradingKey
ARWR Stock Climbs As EU REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released - TechStock²
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization - Yahoo Finance
ARWR Stock Climbs As REDEMPLO Win Fuels Bullish Targets - timothysykes.com
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Benzinga
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
ARWR Stock Climbs As EU Approval And Analyst Targets Heat Up - StocksToTrade
Arrowhead: Stock Up On SHTG DataNo Ceiling On Valuation Growth Potential (NASDAQ:ARWR) - Seeking Alpha
Arrowhead stock jumps on late-stage trial win (ARWR:NASDAQ) - Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) Achieves Late-Stage Trial Succe - GuruFocus
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ARWR Stock Climbs As EU Greenlights REDEMPLO, Street Lifts Targets - StocksToTrade
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
Why is Arrowhead Pharmaceuticals stock surging today? - Investing.com
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma
Arrowhead (ARWR) Shares Surge Over 22% - GuruFocus
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia - BioSpace
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93 By Investing.com - Investing.com South Africa
Why is Arrowhead Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
ARWR Jumps As REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93 - Investing.com
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Yahoo Finance
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):